Toxicological evaluation of peptide compound TSC6: A 13-week subchronic toxicity and genotoxicity study

Area of Science:

• Biochemistry
• Toxicology
• Pharmacology

Background:

• TSC6-peptide is a synthetic 8-amino acid compound designed to inhibit intestinal alpha-amylase.
• It holds potential for managing the digestion and absorption of starchy foods.
• Its toxicological safety and scientific evidence require thorough investigation.

Purpose of the Study:

• To evaluate the safety profile of TSC6-peptide.
• To provide scientific evidence supporting its use as an alpha-amylase inhibitor.
• To conduct in vivo and in vitro toxicological assessments.

Main Methods:

• In vitro genotoxicity testing using reverse mutation assays.
• In vitro genotoxicity testing using mammalian micronucleus assays.
• A 90-day oral dietary toxicity study in rats.

Main Results:

• No genotoxicity was observed for TSC6-peptide in reverse mutation and mammalian micronucleus assays.
• In the 90-day rat study, the No Observed Adverse Effect Level (NOAEL) was 500 mg/kg body weight/day for males.
• The Lowest Observed Adverse Effect Level (LOAEL) for females was 50 mg/kg body weight/day.

Conclusions:

• TSC6-peptide demonstrates a controllable safety profile.
• The findings support its potential utility as an alpha-amylase inhibitor.
• Further research can build upon these established safety parameters.